- Home
- Equities - Stocks - Shares
- Company Press Releases
- GeNeuro: Monthly Statement of Total Voting Rights and Shares Forming The Company’s Share Capital
GeNeuro: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
03 Jan 2023 18:00 CET
Issuer
GENEURO
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
GeNeuro (Paris:GNRO):
Market: Euronext Paris
ISIN code / Mnemo: CH0308403085 / GNRO
Web site: www.geneuro.com
Date |
Number of shares outstanding |
Total voting rights,
|
Total voting rights,
|
December 31, 2021 |
22'320'777 |
22'320'777 |
22'194'754 |
January 31, 2022 |
22'320'777 |
22'320'777 |
22'194'700 |
February 28, 2022 |
22'320'777 |
22'320'777 |
22'192'314 |
March 31, 2022 |
22'320'777 |
22'320'777 |
22'189'722 |
April 30, 2022 |
22'320'777 |
22'320'777 |
22'185'661 |
May 31, 2022 (3) |
24'999'028 |
24'999'028 |
24'865'784 |
June 30, 2022 |
24'999'028 |
24'999'028 |
24'860'213 |
July 31, 2022 |
24'999'028 |
24'999'028 |
24'854'261 |
August 31, 2022 |
24'999'028 |
24'999'028 |
24'853'506 |
September 30, 2022 |
24'999'028 |
24'999'028 |
24'848'222 |
October 31, 2022 |
24'999'028 |
24'999'028 |
24'844'656 |
November 30, 2022 |
24’999’028 |
24’999’028 |
24’848’152 |
December 31, 2022 |
24’999’028 |
24’999’028 |
24’841’446 |
(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is disclosed in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.
(3) Reflecting the capital increase completed on May 12, 2022
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It owns rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005651/en/
GeNeuro
Miguel Payró
CFO
+41 22 552 48 00
investors@geneuro.com
NewCap (France)
Mathilde Bohin (investors)
+33 1 44 71 98 52
Arthur Rouillé (media)
+33 1 44 71 94 98
geneuro@newcap.eu
Source
GENEURO
Provider
BusinessWire
Company Name
GENEURO
ISIN
CH0308403085
Symbol
GNRO
Market
Euronext